Obesity

Weight Management Weight Loss Treatment Options Treatment Weight Loss Treatments Health Risks Causes Medications Childhood Obesity Diabetes

Cochrane Review Finds Intermittent Fasting No Better for Weight Loss

Short, limited studies with patchy adherence leave sustainability plus broader health effects unresolved.

WHO-Backed Reviews Affirm GLP-1 Weight-Loss Gains as Clinicians Flag Safety and Nutrition Gaps

GLP-1 Era Hits the Mainstream With Super Bowl Ads as Costs Rise and Care Shifts to Maintenance

Novo’s New GLP‑1 Pill Tests Lilly’s Lead as Investors Eye Pfizer’s Cheaper Shares

GLP-1 Weight-Loss Boom Triggers Safety Warnings and New Oversight

Pfizer Tops Q4 Estimates but Posts Loss on $4.4 Billion Charge, Reaffirms 2026 Outlook

Eli Lilly Chooses Pennsylvania for $3.5 Billion Plant to Produce Weight-Loss Injectables

AstraZeneca Strikes $1.2 Billion CSPC Pact for Once‑Monthly Obesity and Diabetes Programs

Large MRI Study Links Pancreatic and 'Skinny Fat' Patterns to Faster Brain Aging

New Evidence Flags Rapid Weight Regain After Stopping GLP-1 Drugs

Intermittent Fasting Study Links Weight Loss to Brain–Gut Changes, Fueling Fresh Guidance

Beige Fat Shields Arteries as PRDM16 Loss Drives QSOX1 and High Blood Pressure

Oprah Winfrey Recasts Obesity as Disease in New Book, Backs GLP-1s as Long-Term Care

BMJ Review Finds GLP-1 Weight Loss Largely Reverses Within Two Years After Stopping

Dietitian Urges Health Checks Beyond BMI

JACC Releases First National Cardiovascular Statistics Report for the U.S.

Eli Lilly Prepares €15 Billion Abivax Offer, Eyes Next Wave of Weight-Loss Drugs

New Reviews Recast Weight-Loss Advice Toward Mediterranean, Vegetarian and Fasting Plans

Which? Urges UK to Mandate Front-of-Pack Nutrition Labels

Oxford Review Finds GLP-1 Weight Loss Largely Lost Within About Two Years After Stopping